[Demyelinating encephalomyelitis associated with treatment with adalimumab].
Sillero Sánchez
M
M
García Domínguez
G
G
Asencio Marchante
J J
JJ
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000473:pathology; D004679:Encephalomyelitis / Q000139:chemically induced / Q000473:pathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab